Bone Health in Pediatric Crohn's Disease: A Low Magnitude Mechanical Stimulus Trial

Not Applicable

Completed

Conditions: Crohn Disease

Interventions: Device: Low magnitude mechanical stimulus
Device: Placebo (inactive) low magnitude mechanical stimulus

Registration Number: NCT00364130

Lead Sponsor: Children's Hospital of Philadelphia

Brief Summary: The purpose of this 12-month double blind, placebo controlled randomized trial is to evaluate the effects of daily treatments with low magnitude mechanical stimuli on bone in 160 children with Crohn disease.

Detailed Description: Skeletal growth is characterized by increases in the size of the hard outer layer of bone (cortical bone), and the density of the inner layer of bone (trabecular or "spongy" bone). Children with Crohn disease (CD) have numerous risk factors for impaired bone accumulation, including poor growth, delayed puberty, malnutrition, glucocorticoid therapy and inflammation. We reported that children with CD had significant deficits in trabecular bone mineral density (BMD), cortical dimensions, and muscle mass; bone deficits were strongly associated with muscle deficits. No trials of therapies that build bone or prevent bone breakdown have been conducted in chronic pediatric inflammatory diseases. The capacity to increase bone mass and dimensions in response to mechanical loading is greatest during growth. Recent studies demonstrate that brief daily exposure to low magnitude mechanical stimuli (LMMS) enhances bone mass and quality. This 12-month double blind, placebo controlled randomized trial will evaluate daily 10-minute treatments with LMMS in 160 children with CD. Trabecular BMD, cortical dimensions, and muscle area will be measured by quantitative computed tomography (QCT). The LMMS device monitors adherence; these data will be transmitted by modem to the psychologist who will work closely with subjects to optimize adherence. All subjects will be provided with calcium and vitamin D supplements. The primary aims are to determine if treatment with LMMS results in increased trabecular BMD in the lower leg and spine and increased cortical dimensions in the lower leg in children with CD, compared with placebo controls.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 138

Inclusion Criteria

Age 8-21 years
Diagnosis of Crohn disease > 6 months
Tibia vBMD z-score < 25th%tile for age and sex

Exclusion Criteria

Pregnancy
Weight > 250 lb
Medical illness (unrelated to Crohn)
Cognitive/developmental disorder
Do not speak English
> 1 primary residence
Unwilling to commit to 2 year study
Sibling or cousin enrolled in trial

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Active Low Magnitude Mechanical Stimulus	Low magnitude mechanical stimulus	Active Low Magnitude Mechanical Stimulus
Inactive Low Magnitude mechanical Stimulus	Placebo (inactive) low magnitude mechanical stimulus	Inactive, or placebo low magnitude mechanical stimulus

Primary Outcome Measures

Name	Time	Method
Change in Tibia Trabecular Volumetric Bone Mineral Density (BMD) Z-score at 12 Months	12 months	We calculated the mean change in tibia trabecular volumetric BMD Z-score between baseline and 12 months, as measured by peripheral quantitative computed tomography (pQCT). The Z-score, or Standard Deviation Score, is a measure of the number of standard deviations that an individual is above or below the median value in a healthy child or adolescent of the same age, sex and race. For example, a Z-score of 0 means that an individual's result is equivalent to the 50th percentile in a healthy population. A Z-score of -1.0 means that an individual's result is equovalent to the 16th percentile in a healthy population.
Change in Spine Volumetric BMD Z-score at 12 Months	12 months	We calculated the mean change in spine volumetric BMD Z-score, as measured by QCT, between baseline and 12 months
Change in Tibia Cortical Area Z-score 12 Months	12 months	We calculated the mean change in tibia cortical area Z-score, as measured by pQCT, between baseline and 12 months.

Secondary Outcome Measures

Name	Time	Method
Change in Total Hip Areal BMD Z-score Between Baseline and 12 Months	12months	We calculated the mean change in total hip bone mineral density z-score, as measured by DXA, between baseline and 12 months
Change in QCT Tibia Trabecular Volumetric BMD at 12 Months	12 months	We calculated the mean change in tibia trabecular volumetric BMDbetween baseline and 12 months as measured by (QCT)
Change in Posteroanterior Lumbar Spine Areal BMD Z-score	12 months	We calculated the mean change in posterior anterior lumbar spine areal BMD Z-score between baseline and 12 months as measured by DXA
Change in Femoral Neck Areal BMD Z-score Between Baseline and 12 Months	12 months	We calculated the mean change in femoral neck areal bmd Z-score between baseline and 12 months as measured by DXA
Change in Whole Body Bone Mineral Content Z-score Between Baseline and 12 Months	12 months	We calculated the mean change in whole body bone mineral content Z-score, as measured by DXA, between baseline and 12 months